Compare AstraZeneca plc (AZN) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs State Street Technology Select Sector SPDR ETF — how do they compare? AstraZeneca plc trades at $168.98 (market cap $253.13B), while State Street Technology Select Sector SPDR ETF trades at $181.58. The key difference: AstraZeneca plc pays a 1.92% dividend while State Street Technology Select Sector SPDR ETF pays none, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | XLK | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $209.48 | $198.21 |
52-Week Low | $137.44 | $127.49 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
XLK trades at $181.28, down 2.43% on the day, with technical indicators showing a bearish moving average trend but neutral oscillators. The ETF has delivered strong year-to-date performance, gaining 33% as of July 2, 2026 (ETF Trends), driven by technology sector leadership. Recent news highlights robust Q2 earnings expectations and institutional inflows into tech ETFs.
Outlook remains cautiously optimistic given sector momentum and earnings growth projections, though risks include market concentration and valuation concerns. The neutral technical signal suggests near-term consolidation, while fundamental strength in tech supports long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
